Particularly in lung adenocarcinomas, ERCC1 has been shown to be associated with unchanged EGFR mutation status [16], to predict response to cisplatin-based therapies and also to be of prognosis value by itself [19, 47, 48]. This evidence concerns the gene ERCC1 and lung adenocarcinoma.